Around 49% of the more than 300 healthcare providers, hospital/health system executives, payers, advocacy groups, and academics surveyed by Get the Medications Right™ (GTMRx) Institute said the cost of healthcare is the biggest issue they face.
The cost of healthcare is the biggest issue healthcare leaders face, a new survey says. Plus, communication between prescribers and pharmacists is the top concern in medication management.
Around 49% of the more than 300 healthcare providers, hospital/health system executives, payers, advocacy groups, and academics surveyed by Get the Medications Right™ (GTMRx) Institute said the cost of healthcare is the biggest issue they face.
Related: COVID-19 pushes up prescription drug spending of healthcare systems
Similarly, a separate report, the American Society of Health-System Pharmacists’ (ASHP) National Trends in Prescription Drug Expenditures and Projections for 2021 found costs related to the pandemic will continue to be a significant driver of healthcare systems’ drug expenditures in 2021, along with uptake in the use of biosimilars, a large pipeline of new cancer drugs, and increased approvals of specialty medications.
Prescription drug spending in 2020 grew at a moderate rate of 4.9% to $535.3 billion, driven by increased utilization. Spending on new drugs accounted for 1.8% of the increase, and price changes accounted for 0.3%.
IN the GTMRx survey, 27% said that personal silos preventing integrated patient-centered care is the biggest healthcare issue, while 16.5% named access to healthcare and 7% said appropriately managing medications.
Fifty percent said lack of communication is the biggest issue in medication management, while 36% said the cost of medications is the top concern, and nearly 13% called out a “trial and error” approach to prescribing as the biggest concern.
Related: Express Scripts report: top drug classes driving spending growth
“The major discussion around pharmacy benefits centers on access to and affordability of drugs, but the elephant in the room is appropriate use of all medications,” said Katherine H. Capps, co-founder and executive director of The GTMRx Institute, in a press release. “We must find a better way to optimize medication use to avoid life-threatening and wasteful overuse, misuse and underuse.”
Capps contends that a move toward comprehensive medication management (CMM), in which physicians and pharmacists individuals assess the appropriateness, effectiveness, and safety of each medication, is a solution.
Although more than 96% of those surveyed believe a more comprehensive and integrated way to manage medications, 44% said that CMM is not well understood or not understood at all in their immediate network.
Nearly 84% of respondents believe that wide adoption of CMM could help stem the opioid addiction crisis.
Read more: Novel IV opioid will be available this year
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More